Accessibility Menu
Novozymes A/s logo

Novozymes A/s(OTC) NVZMY

Market Cap$28.07BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)+1,891%
5 Year-7%
1 Year+9%
1 Month+5%
$68.06
-3.20%
-2.25Today
Novozymes A/s last closing stock price
MetricPriceDate
Last closeUSD 68.062026-09-04
Novozymes A/s stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.85%USD 71.532026-08-28
1 month+4.87%USD 64.902026-08-05
3 month+21.14%USD 56.182026-06-05
Year to date+8.79%USD 62.562025-12-31
1 year+9.46%USD 62.182025-09-04
3 year+64.02%USD 41.492023-09-05
5 year-6.5%USD 72.792021-09-03
Since inception+1,891.38%USD 3.422003-02-24

Novozymes A/s Financials at a Glance

Market Cap

$28.07BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€4.33B

Net Income (TTM)

-€253.80M

EPS (TTM)

$1.58

P/E Ratio

43.05

Dividend

$1.02

Beta (Volatility)

0.47 (Low)

Price

$68.06

Volume

12,772

Open

$66.58

Previous Close

$68.06

Daily Range

$66.58 - $68.85

52-Week Range

$49.90 - $75.27

Estimated Earnings Date

Nov 5, 2026

NVZMY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Novozymes A/s

Novozymes A/S is a global biotechnology firm specializing in the creation and distribution of industrial enzymes, microorganisms, and probiotics. With a strong operational presence across multiple regions, Novozymes serves various sectors, including food and beverages, agriculture, and household care.

Products and Services
  • Industrial enzymes for food processing and beverages
  • Innovative solutions for agriculture and animal health
  • Specialized formulations for household cleaning products
Growth Outlook
  • Revenue growth of 2.5% year-over-year in the latest quarter
  • Strong demand in the agriculture sector driving innovation
  • Expansion into emerging markets expected to enhance market share
Financial Highlights
  • Recent quarterly revenue of 1.13 billion EUR, reflecting stable performance
  • Net income of 174.5 million EUR in the latest quarter
  • TTM gross profit margin of 54.9%, indicating operational efficiency
Novozymes A/S has established itself as a leader in the biotechnology sector, focusing on sustainable solutions that cater to diverse industries. The company's commitment to innovation is evident in its extensive product offerings, which not only enhance productivity but also promote environmental sustainability. Recent financial performance showcases resilience, with a steady revenue stream and a robust net income, reflecting effective cost management and operational efficiency. The growth outlook remains positive, driven by increasing demand in key sectors and strategic expansion into new markets. This positions Novozymes favorably for future growth, making it an intriguing option for potential investors interested in the biotechnology and sustainability sectors.
AI Generated • Aug 24, 2026

Industry

Chemicals

Sector

Materials

Employees

11,641

CEO

Ester Baiget, MBA

Website

www.novonesis.com

Headquarters

Lyngby, ND 2800, DK

NVZMY Financials

Key Financial Metrics (TTM)

Gross Margin

54.89%

Operating Margin

21.24%

Net Income Margin

14.70%

Return on Equity

5.79%

Return on Capital

2.65%

Return on Assets

3.80%

Earnings Yield

2.32%

Dividend Yield

1.49%

Payout Ratio

64.22%

Stock Overview

Market Cap

$28.07BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

412.50M

Volume

12.77K

Avg. Volume

33.95K

Financials (TTM)

Gross Profit

€2.38B

Operating Income

€958.87M

EBITDA

€1.45B

Operating Cash Flow

€4.32B

Capital Expenditure

-€1.12B

Free Cash Flow

€3.20B

Cash & ST Invst.

€313.47M

Total Debt

€3.07B

Novozymes A/s Performance Analysis

Novozymes A/s annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 2,479,729,1234.4%
20232023-12-31EUR 2,597,085,2684.7%
20242024-12-31EUR 4,146,660,60159.7%
20252025-12-31EUR 4,692,176,29913.2%
Novozymes A/s sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30677.2%
Q42025-12-31-6.1%
Q12026-03-3114.2%
Q22026-06-30-0.3%
Novozymes A/s annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 1.864.4%
20232023-12-31EUR 1.58-15.2%
20242024-12-31EUR 0.72-54.4%
20252025-12-31EUR 1.4195.7%
Novozymes A/s sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30671.2%
Q42025-12-31-13.3%
Q12026-03-3165.4%
Q22026-06-30-14.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€1.13B

+731.2%

Gross Profit

€631.99M

+766.0%

Gross Margin

55.70%

N/A

Market Cap

$28.07BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.41M

N/A

Employees

11,641

N/A

Net Income

€171.61M

+835.9%

EBITDA

€421.67M

+1331.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€313.47M

-14.2%

Total Debt

€3.07B

-7.7%

Accounts Receivable

€930.92M

+8.3%

Inventory

€835.95M

+4.5%

Long Term Debt

€2.83B

-4.9%

Short Term Debt

€237.20M

-31.6%

Return on Assets

3.80%

N/A

Return on Invested Capital

5.91%

N/A

Free Cash Flow

€263.41M

+10.7%

Operating Cash Flow

€364.07M

+13.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EMSHFEms-Chemie Holding AG
$979.75-0.00%
AKZOYAkzo Nobel N.V.
$23.50+0.09%
GVDNYGivaudan S.A.
$80.08-1.77%
SKFOFSika AG
$234.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About NVZMY

What is the current price of Novozymes A/s?

Novozymes A/s is trading at $68.06 per share.

What is the 52-week range for Novozymes A/s?

Over the past 52 weeks, Novozymes A/s has traded between $49.90 and $75.27.

How much debt does Novozymes A/s have?

As of the most recent reporting period, Novozymes A/s reported total debt of €3.51B.

How much cash does Novozymes A/s have on hand?

Novozymes A/s reported €352.94M in cash and cash equivalents in its most recent financial results.

What is Novozymes A/s’s dividend yield?

Novozymes A/s currently has a dividend yield of 1.49%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services